重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病的效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (543 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease. Methods A total of 100 patients with Parkinson′s disease admitted to Chenzhou NO.1 People′s Hospital, Hu′nan Province from November 2016 to October 2019 were selected and divided into the study group and the control group by random number table method, with 50 patients in each group. The control group was treated with Selegiline, and the study group was treated with Rivastigmine Hydrogen Tartrat Capsules on the basis of the control group. Both groups were treated for 8 weeks. The curative effect, the scores of WHO quality of life (WHOQOL-BREF), Parkinson′s disease rating scale (UPDRS) and autonomic nerve symptom scale (SCOPT-AUT), montreal cognitive assessment scale (MoCA), the levels of insulin-like growth factor (IGF-1), β-amyloid protein 1-42 (Aβ1-42) and dopamine transporter (DAT) activity activity in the affected side and healthy side were compared between the two groups. The adverse reactions during the treatment in both groups were recorded. Results After 8 weeks of treatment, the total clinical effective rate of the study group was higher than that of the control group, with statistically significant difference (P ＜ 0.05). After 8 weeks of treatment, WHOQOL-BREF and MOCA scores, the levels of Aβ1-42 and IGF-1 were all higher in both groups than those before treatment, and the study group was higher than the control group; UPDRS and SCOPT-AUT scores were both lower than those before treatment, and the study group was lower than the control group, with statistically significant differences (P ＜ 0.05). After 8 weeks of treatment, the DAT activity in the affected side of both groups and the healthy side of the control group decreased compared with that before treatment, and the differences were statistically significant (all P ＜ 0.05). The DAT activity in the healthy side of the study group after 8 weeks of treatment was not significantly different from that before treatment (P ＞ 0.05). After 8 weeks of treatment, the DAT activity of both the affected side and the healthy side of the study group was higher than that of the control group, with statistically significant differences (all P ＜ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Treatment of Parkinson′s disease with Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline can rapidly improve the clinical symptoms of patients, improve serum Aβ1-42 and IGF-1 levels, delay the rate of DAT inactivation, and do not increase the incidence of adverse reactions, the effect is significant.

Key words： Rivastigmine Hydrogen Tartrat Capsules Selegiline Parkinson′s disease Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LEI Yuanbiao1 LEI Yu2 OU Fuyong1 YI Jiping1

Cite this article:

LEI Yuanbiao1 LEI Yu2 OU Fuyong1 YI Jiping1. Effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease[J]. 中国医药导报, 2020, 17(23): 62-65,69.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I23/62

[1] Zhai H，Kang Z，Zhang H，et al. Baicalin attenuated substantia nigra neuronal apoptosis in Parkinson′s disease rats via the mTOR/AKT/GSK-3β pathway [J]. J Integr Neurosci，2019，18（4）：423-429.
[2] 孙静，熊航，姚玉玺.帕金森病的治疗进展[J].医学综述，2020，26（6）：1157-1160，1165.
[3] 叶虹，罗丽霞，李飞，等.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察[J].中国医药导报，2014， 11（28）：58-61.
[4] 张立芳，李博.高压氧联合司来吉兰治疗帕金森病合并睡眠障碍的效果观察[J].广西医科大学学报，2019，36（8）：1361-1365.
[5] Zhang XR，Zhang ZR，Chen SY，et al. β-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson′s rats [J]. Aging （Albany NY），2019，11（24）：12315-12327.
[6] 朱冬梅，熊学智.左旋多巴联合卡巴拉汀治疗对帕金森病患者肌强直及多巴转运体的影响[J].医学临床研究，2018，35（5）：876-878，882.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第三版）[J].中华神经科杂志，2014（6）：428-433.
[8] 丁荣楣，王平，马丽君，等.应用两种国际生存量表评价榄香稀注射液对非小细胞肺癌患者生存质量的影响[J].临床肺科杂志，2015，20（2）：230-233.
[9] 康霞.神经干细胞移植治疗帕金森病的效果观察[J].中国实用神经疾病杂志，2018，21（11）：1233-1237.
[10] 郑能慆，田书娟，李慎军，等.多发性硬化患者神经系统损害程度与自主神经症状量表评分和交感神经皮肤反应异常率的关系[J].临床神经病学杂志，2016，29（2）：143-145.
[11] 郁芳芳，王兰，刘澄英，等.蒙特利尔认知评估量表在筛查COPD患者轻度认知功能障碍的价值[J].临床肺科杂志，2018，23（11）：2045-2047.
[12] 胡瑾.普拉克索治疗帕金森临床效果分析[J].河北医药，2014（9）：1318-1319.
[13] 刘疏影，陈彪.帕金森病流行现状[J].中国现代神经疾病杂志，2016，16（2）：98-101.
[14] 范秀博，李毓新，吉智，等.奥匹卡朋联合左旋多巴治疗帕金森病的疗效及安全性分析[J].疑难病杂志，2019， 18（2）：114-118.
[15] Camacho-Conde JA，Campos-Arillo VM. The phenomenology of pain in Parkinson′s disease [J]. Korean J Pain，2020，33（1）：90-96.
[16] Kashezhev AG，Sinkin MV，Kulikov AG，et al. Impact of rhythmic transcranial magnetic stimulation on the dynamics of motor and non-motor manifestations of Parkinson′s disease [J]. Vopr Kurortol Fizioter Lech Fiz Kult，2019，96（6）：17-21.
[17] 李振光，李刚，于占彩，等.卡巴拉汀对帕金森病认知功能障碍及跌倒的影响[J].中华临床医师杂志：电子版，2015（19）：3549-3553.
[18] 高岩，赵亚明.卡巴拉汀联合左旋多巴治疗帕金森病的临床研究[J].现代药物与临床，2018，33（5）：1234-1238.
[19] 王妍，吴保鑫，马正磊，等.利斯的明对无痴呆无抑郁帕金森病患者冷漠症状的影响[J].神经损伤与功能重建，2017，12（2）：156-158.
[20] Henderson EJ，Lord SR，Brodie MA，et al. Rivastigmine for gait stability in patients with Parkinson′s disease（ReSPonD）：a randomised， double-blind， placebo-controlled， phase 2 trial [J]. Lancet Neurol，2016，15（3）：249-258.
[21] 蒋洋洋，张虹玮.帕金森病伴焦虑抑郁状态的中西医治疗进展[J].疑难病杂志，2018，17（9）：967-972.
[22] 吴薇薇，谢海洋，邵祥忠，等.盐酸多奈哌齐片联合左旋多巴治疗帕金森病临床疗效[J].临床军医杂志，2019， 47（11）：1227-1228.